■ Enolase-1 Antibody Drug Conjugate (ADC)
Activated immune cells or cancer cells express surface ENO1 to facilitate their motility or function. We have two ADC programs to gather proof-of-concept in vivo efficacy of HL547 and HL427 for immunology and oncology use, respectively.
■ Preclinical Programs
HL547 is an immunomodulatory ADC in which steroids are conjugated to HuniLife’s proprietary ENO1 antibody HuL001, while H427 is an anti-cancer ADC in which cytotoxic drugs are conjugated.
➣ HL547 for Inflammatory Bowel Disease (IBD)
IBD, also known as Crohn’s disease (CD) and ulcerative colitis (UC), is characterized by chronic inflammation of the gastrointestinal tract. IBD usually involve severe diarrhea, abdominal pain, weight loss and life-threatening in extreme cases. Existing treatments aim to reduce the inflammation that triggers the symptoms. The medications available for IBD include anti-inflammatory drugs and biologics. Surgery may be required to remove the diseased segment of bowel when medications can no longer control the symptoms. Currently, no medications could adequately treat all IBD patients. The patient might not respond to existing medications or lose response over time. Therefore, the demand for new IBD cures continue to be high. HL547 is developed to specifically deliver immunosuppressant to ENO1-expressed inflammatory monocytes and macrophages. The approach is expected to reduce off-target side effects and elevate dose-limited efficacy of steroids or immunosuppressant.
➣ HL427 for Castration-Resistant Prostate Cancer (CRPC)
We have showed preclinical efficacy of targeting ENO1 in CRPC in HL227 program. HL427 is further developed to explore whether ENO1-targeting ADC has advanced anti-cancer efficacy in preclinical CRPC or metastatic CRPC models.
